Please ensure Javascript is enabled for purposes of website accessibility

3 Critical Catalysts on the Way for Inovio

By Keith Speights – Sep 22, 2020 at 6:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With three important milestones just ahead, the biotech stock will likely soar or sink in the near future.

Inovio Pharmaceuticals (INO -5.47%) tends to stir up strong feelings among investors. Bulls would be quick to point out that the stock is up over 430% so far this year, an impressive gain by any standard. Bears would likely counter that those gains were made in the first half of 2020. Inovio has lost much of its steam in recent months.

Regardless of what you think about Inovio, there's no question that the next few weeks and months will be very important for the biotech stock. Here are three critical catalysts on the way for Inovio.

Wooden blocks forming a picture of a rocket taking off

Image source: Getty Images.

1. Start of phase 2/3 study of INO-4800

Inovio has repeatedly stated that it plans to begin a phase 2/3 study of coronavirus vaccine candidate INO-4800 in September. But the clock is ticking to meet that goal.

What's the holdup? The company must first receive a thumbs-up from the Food and Drug Administration before it can advance INO-4800 into the next phase of clinical testing.  

Inovio CEO Joseph Kim recently stated that the biotech will use the intermediary phase 2/3 process to determine what dose to administer to participants in the phase 3 portion. He said that the phase 3 part of the study is designed similarly to those of other COVID-19 vaccine candidates already in late-stage testing.

2. External funding deal

Inovio ended the second quarter in a pretty good cash position. The company reported nearly $372 million in cash, cash equivalents, and short-term investments as of June 30, 2020. However, Inovio's expenses will be much higher if it conducts a large late-stage clinical trial for INO-4800 and manufactures large quantities of the vaccine to secure supply agreements.

The company will almost certainly need more money. Kim said at the Cantor 2020 Global Virtual Healthcare Conference last week that an external funding deal is on the way to support the phase 2/3 study of INO-4800. Perhaps most importantly, Kim stated that the company expects to announce third-party funding this month.

Several of Inovio's rivals have secured funding from Operation Warp Speed, the U.S. government program established to accelerate the development of coronavirus vaccines. However, Inovio could be in discussions with other players to help fund its late-stage study. Based on Kim's comments, investors shouldn't have to worry about another stock offering. Kim said that the funding would be non-dilutive.

3. Key results for VGX-3100

With all of the buzz about INO-4800, it's sometimes easy to forget that Inovio's lead pipeline candidate is actually VGX-3100. And the company expects to announce important results for the DNA medicine soon.

Inovio should report results from the phase 3 study of VGX-3100 in treating human papillomavirus (HPV)-related precancerous cervical dysplasia in the fourth quarter of this year. Depending on those results, the company could be in a position to move forward with a regulatory filing next year.

That's not the only upcoming milestone for VGX-3100. Inovio also expects to announce full data from its phase 2 clinical studies of VGX-3100 in treating HPV-related anal and vulvar dysplasia in Q4. The biotech already reported positive interim results from these studies.

Big news and big moves 

Each of these three developments could provide significant catalysts for Inovio. If the company receives a green light from the FDA for advancing INO-4800 plus a major external funding deal over the next couple of weeks, the stock would likely soar. We could even see a short squeeze unfold, considering that around 31% of Inovio's outstanding shares are sold short. Positive results for VGX-3100 later this year would be the icing on the cake.

On the other hand, investors won't react very well if there are significant delays or bad news on any of these fronts. Inovio seems destined for big news and big moves -- one way or the other.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
INO
$1.90 (-5.47%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.